Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Critical reviews in oncology/hematology
2025
|
| Sujets: | |
| Accès en ligne: | https://pubmed.ncbi.nlm.nih.gov/40194716/ |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy. Liang, Anqi Tao, Tao Chen, Jiahui Yang, Yucong Zhou, Xiaorong Zhu, Xiao Yu, Guiping Humans Neoplasms Lab-On-A-Chip Devices Tumor Microenvironment Immunotherapy Animals Drug Screening Assays, Antitumor Antineoplastic Agents Tumor is one of the major diseases endangering human health while establishing an efficient in vitro tumor microenvironment (TME) model, which is an effective way to reveal the nature of the tumor and develop therapeutic methods. In recent years, due to the continuous development of lab-on-a-chip technology and tumor biology, various tumor-on-a-chip models applied to oncology research have emerged. Among them, the Immunotherapy-on-a-chip (ITOC) platform stands out with its ability to reflect immunological behavior in the TME. It is a class of in vitro tumor-on-a-chip with immune activity, which has good performance and the ability to reproduce TME. It can highly simulate the complex pathophysiological characteristics of tumors and be used to study various features related to tumor biological behavior. Currently, many advantageous functions and application values of ITOC platforms have been discovered and applied to tumor drug screening and development, tumor immunotherapy, and personalized therapy. In conclusion, the tumor-on-a-chip platform is a highly promising model for medical oncology research. In this review, the background of the ITOC platform, key factors for constructing an ideal ITOC platform, and the specific applications of ITOC platforms in tumor research and treatment are introduced.